← Evidence map

ArticleFrontiers in oncology2026

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in

Simran Chandra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in | OpenQuestion